← Oncology Approval Tracker

FDA DECISION ·

Xalkori oral pellets

crizotinib · Pfizer

FDA approvalNew formulationMultiple cancer types
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An oral pellet presentation for approved ALK- or ROS1-positive metastatic NSCLC in adults, ALK-positive relapsed or refractory systemic anaplastic large cell lymphoma in children aged one year or older and young adults, and unresectable, recurrent or refractory ALK-positive inflammatory myofibroblastic tumor in adults and children aged one year or older.

LAMPGEN ANALYSIS

Why it matters

The formulation provides an alternative to swallowing intact crizotinib capsules.

What research teams should watch

Train patients and caregivers on opening the pellet shell and preparing the full dose according to the formulation's label.

PRIMARY RECORDS

Sources